FR3062063B1 - Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques - Google Patents

Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques Download PDF

Info

Publication number
FR3062063B1
FR3062063B1 FR1750629A FR1750629A FR3062063B1 FR 3062063 B1 FR3062063 B1 FR 3062063B1 FR 1750629 A FR1750629 A FR 1750629A FR 1750629 A FR1750629 A FR 1750629A FR 3062063 B1 FR3062063 B1 FR 3062063B1
Authority
FR
France
Prior art keywords
hematopoietic stem
stem cell
fecal
microbiote
treating patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1750629A
Other languages
English (en)
French (fr)
Other versions
FR3062063A1 (fr
Inventor
Mohamad Mohty
Harry SOKOL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université Pierre et Marie Curie
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Original Assignee
Centre National de la Recherche Scientifique
Université Pierre et Marie Curie
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Sorbonne Université
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59325347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR3062063(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique, Université Pierre et Marie Curie, Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Sorbonne Université filed Critical Centre National de la Recherche Scientifique
Priority to FR1750629A priority Critical patent/FR3062063B1/fr
Priority to CA3051807A priority patent/CA3051807C/fr
Priority to SI201830842T priority patent/SI3573631T1/sl
Priority to PT187029525T priority patent/PT3573631T/pt
Priority to AU2018212530A priority patent/AU2018212530B2/en
Priority to FIEP18702952.5T priority patent/FI3573631T3/fi
Priority to KR1020197024970A priority patent/KR102517287B1/ko
Priority to HRP20230122TT priority patent/HRP20230122T1/hr
Priority to US16/480,863 priority patent/US20200188450A1/en
Priority to EP18702952.5A priority patent/EP3573631B1/fr
Priority to ES18702952T priority patent/ES2937965T3/es
Priority to PL18702952.5T priority patent/PL3573631T3/pl
Priority to JP2019540408A priority patent/JP7527109B2/ja
Priority to IL268237A priority patent/IL268237B/en
Priority to HUE18702952A priority patent/HUE061155T2/hu
Priority to LTEPPCT/EP2018/051941T priority patent/LT3573631T/lt
Priority to PCT/EP2018/051941 priority patent/WO2018138251A1/fr
Priority to RS20230101A priority patent/RS63978B1/sr
Priority to CN201880008477.0A priority patent/CN110520141A/zh
Priority to DK18702952.5T priority patent/DK3573631T3/da
Publication of FR3062063A1 publication Critical patent/FR3062063A1/fr
Publication of FR3062063B1 publication Critical patent/FR3062063B1/fr
Application granted granted Critical
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR1750629A 2017-01-26 2017-01-26 Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques Expired - Fee Related FR3062063B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR1750629A FR3062063B1 (fr) 2017-01-26 2017-01-26 Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
ES18702952T ES2937965T3 (es) 2017-01-26 2018-01-26 Microbiota fecal para el tratamiento de pacientes con trasplante de células madre hematopoyéticas
JP2019540408A JP7527109B2 (ja) 2017-01-26 2018-01-26 造血幹細胞移植を受けている患者を治療するための便細菌叢
PT187029525T PT3573631T (pt) 2017-01-26 2018-01-26 Microbiota fecal para tratar pacientes que são submetidos a um transplante de células estaminais hematopoiéticas
AU2018212530A AU2018212530B2 (en) 2017-01-26 2018-01-26 Fecal microbiota for treating patients undergoing a hematopoietic stem cell transplant
FIEP18702952.5T FI3573631T3 (fi) 2017-01-26 2018-01-26 Ulostemikrobisto hematopoieettisten kantassolujen siirron saavien potilaiden hoitoon
KR1020197024970A KR102517287B1 (ko) 2017-01-26 2018-01-26 조혈 줄기 세포 이식을 받는 환자를 치료하기 위한 분변 미생물총
HRP20230122TT HRP20230122T1 (hr) 2017-01-26 2018-01-26 Fekalna mikrobiota za liječenje bolesnika kod kojih se vrši transplantacija hematopoetskih matičnih stanica
US16/480,863 US20200188450A1 (en) 2017-01-26 2018-01-26 Fecal microbiota for treating patients undergoing a hematopoietic stem cell transplant
EP18702952.5A EP3573631B1 (fr) 2017-01-26 2018-01-26 Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
CA3051807A CA3051807C (fr) 2017-01-26 2018-01-26 Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
PL18702952.5T PL3573631T3 (pl) 2017-01-26 2018-01-26 Mikrobiota kałowa w leczeniu pacjentów poddawanych przeszczepowi hematopoetycznych komórek macierzystych
SI201830842T SI3573631T1 (sl) 2017-01-26 2018-01-26 Fekalna mikrobiota za zdravljenje bolnikov pri presaditvi matičnih hematopoetskih celic
IL268237A IL268237B (en) 2017-01-26 2018-01-26 Fecal microbiota for treating patients undergoing a hematopoietic stem cell transplant
HUE18702952A HUE061155T2 (hu) 2017-01-26 2018-01-26 Széklet-mikrobióta hematopoietikus õssejtek transzplantációjának alávetett páciensek kezelésére
LTEPPCT/EP2018/051941T LT3573631T (lt) 2017-01-26 2018-01-26 Išmatų mikrobiota, skirta gydyti pacientams, kuriems transplantuojamos hemapoetinės kamieninės ląstelės
PCT/EP2018/051941 WO2018138251A1 (fr) 2017-01-26 2018-01-26 Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
RS20230101A RS63978B1 (sr) 2017-01-26 2018-01-26 Fekalna mikrobiota za lečenje bolesnika kod kojih se vrši transplantacija hematopoetskih matičnih ćelija
CN201880008477.0A CN110520141A (zh) 2017-01-26 2018-01-26 用于治疗接受造血干细胞移植的患者的粪便微生物群
DK18702952.5T DK3573631T3 (da) 2017-01-26 2018-01-26 Fækal mikrobiota til behandling af patienter med en transplantation af hæmatopoietiske stamceller

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1750629 2017-01-26
FR1750629A FR3062063B1 (fr) 2017-01-26 2017-01-26 Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques

Publications (2)

Publication Number Publication Date
FR3062063A1 FR3062063A1 (fr) 2018-07-27
FR3062063B1 true FR3062063B1 (fr) 2019-04-19

Family

ID=59325347

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1750629A Expired - Fee Related FR3062063B1 (fr) 2017-01-26 2017-01-26 Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques

Country Status (20)

Country Link
US (1) US20200188450A1 (enExample)
EP (1) EP3573631B1 (enExample)
JP (1) JP7527109B2 (enExample)
KR (1) KR102517287B1 (enExample)
CN (1) CN110520141A (enExample)
AU (1) AU2018212530B2 (enExample)
CA (1) CA3051807C (enExample)
DK (1) DK3573631T3 (enExample)
ES (1) ES2937965T3 (enExample)
FI (1) FI3573631T3 (enExample)
FR (1) FR3062063B1 (enExample)
HR (1) HRP20230122T1 (enExample)
HU (1) HUE061155T2 (enExample)
IL (1) IL268237B (enExample)
LT (1) LT3573631T (enExample)
PL (1) PL3573631T3 (enExample)
PT (1) PT3573631T (enExample)
RS (1) RS63978B1 (enExample)
SI (1) SI3573631T1 (enExample)
WO (1) WO2018138251A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200038506A (ko) * 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
US20220023419A1 (en) * 2018-11-28 2022-01-27 The Council Of The Queensland Institute Of Medical Research Inhibiting inflammation
CN112375705A (zh) * 2020-11-12 2021-02-19 安徽燕婉健康科技有限公司 一种替代天然菌群的肠壁移植优势菌的制备方法及其应用
EP4386090A1 (en) * 2022-12-12 2024-06-19 Assistance Publique - Hôpitaux De Paris Method for determining and improving the potential efficacy of anticancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2649719B1 (fr) * 1989-07-17 1993-08-27 Cerbio Sa Procede de protection et de conservation de micro-organismes notamment de bacteries
BR112013022927A2 (pt) * 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
CN104918624A (zh) * 2012-11-26 2015-09-16 托马斯·朱利叶斯·波洛迪 恢复排泄物微生物群的组合物及其制造和使用方法
WO2016057671A1 (en) * 2014-10-07 2016-04-14 University Of Virginia Patent Foundation Compositions and methods for preventing and treating infection
ES3010296T3 (en) * 2014-11-25 2025-04-02 Memorial Sloan Kettering Cancer Center Intestinal microbiota and gvhd
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
FR3035328B1 (fr) * 2015-04-24 2019-08-23 Maat Pharma Procede de preparation d'un echantillon de microbiote fecal
US20180185421A1 (en) * 2016-08-29 2018-07-05 Tokyo Metropolitan Government Composition comprising fecal microbiota

Also Published As

Publication number Publication date
KR102517287B1 (ko) 2023-03-31
PL3573631T3 (pl) 2023-05-02
RS63978B1 (sr) 2023-03-31
IL268237A (en) 2019-09-26
AU2018212530A1 (en) 2019-09-05
EP3573631A1 (fr) 2019-12-04
SI3573631T1 (sl) 2023-09-29
US20200188450A1 (en) 2020-06-18
AU2018212530B2 (en) 2022-06-23
CN110520141A (zh) 2019-11-29
PT3573631T (pt) 2023-01-24
ES2937965T3 (es) 2023-04-03
CA3051807A1 (fr) 2018-08-02
FI3573631T3 (fi) 2023-03-02
JP7527109B2 (ja) 2024-08-02
KR20190130563A (ko) 2019-11-22
FR3062063A1 (fr) 2018-07-27
HUE061155T2 (hu) 2023-05-28
JP2020506183A (ja) 2020-02-27
WO2018138251A1 (fr) 2018-08-02
HRP20230122T1 (hr) 2023-03-31
CA3051807C (fr) 2023-07-11
IL268237B (en) 2022-07-01
EP3573631B1 (fr) 2022-11-16
LT3573631T (lt) 2023-03-10
DK3573631T3 (da) 2023-01-30

Similar Documents

Publication Publication Date Title
Charitos et al. Stem cells: a historical review about biological, religious, and ethical issues
BR112021022458A2 (pt) Células pluripotentes modificadas ou uma célula derivada das mesmas, método de transplantar uma célula, método de tratamento de uma doença em um paciente em necessidade de células transplantadas, método para gerar uma célula pluripotente modificada, método para gerar uma célula hipoimunogênica pluripotente, e método de transplante de uma célula pluripotente hipoimunogênica (hip) ou célula derivada da mesma
BR112018076306A2 (pt) composições e métodos para a supressão de células cd117+
MX2021004579A (es) Métodos para trasplante de células madre hematopoyéticas alogénicas.
WO2019084057A3 (en) Compositions and methods for the depletion of cd117+ cells
BR112018076263A2 (pt) composições e métodos para a depleção de células
BR112017000464A2 (pt) células gama delta t e uso das mesmas
BR112022004562A2 (pt) Método de seleção de doador universal para identificar doadores de células nk
EA202090922A1 (ru) Композиции и способы истощения cd2+ клеток
EA201990583A1 (ru) Клеточная суспензия для использования в лечении заболевания периферических артерий нижних конечностей
MX2022001967A (es) Composiciones de células t específicas para virus de terceros y métodos para prepararlas y usarlas en profilaxis antiviral.
MX2021009626A (es) Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas.
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
DE69634982D1 (de) Verfahren zur steigerung von hematopoietischen zellen
SG11201900986YA (en) Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
HRP20230122T1 (hr) Fekalna mikrobiota za liječenje bolesnika kod kojih se vrši transplantacija hematopoetskih matičnih stanica
Zhang et al. Adoptive transfer of DNT cells induces long-term cardiac allograft survival and augments recipient CD4+ Foxp3+ Treg cell accumulation
Väkevä et al. Allogeneic Haematopoietic Stem Cell Transplantation for Patients with Cutaneous T-cell Lymphoma.
JOP20200075A1 (ar) طرق لعلاج حالات عدوى بكتيرية
Garming-Legert et al. Enhanced oral healing following local mesenchymal stromal cell therapy
EA202090990A1 (ru) Системы и способы получения в-клеток генетически модифицированных для экспрессии выбранных антител
JAISINGH STEM CELLS AND THEIR APPLICATIONS
EA202191442A1 (ru) Аллогенные car т-клетки, полученные из плаценты, и их применение
Wang et al. Retracted: An evaluation of allogeneic freeze-dried concentrated growth factors biocompatibility in vitro and in vivo
Campara et al. Living donor parathyroid allotransplantation.: abstract# C1587

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20180727

AU Other action affecting the ownership or exploitation of an industrial property right

Effective date: 20181003

CL Concession to grant licences

Name of requester: MAAT PHARMA, FR

Effective date: 20181003

Name of requester: SATT LUTECH, FR

Effective date: 20181003

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

ST Notification of lapse

Effective date: 20240905